Skip to content
The Peptide Effect
Comparison

Sermorelin vs Tesamorelin

Sermorelin and tesamorelin are both growth hormone releasing hormone (GHRH) analogs that stimulate the pituitary to produce natural GH, but they occupy very different positions in clinical medicine. Tesamorelin (brand name Egrifta) is the only GHRH analog currently FDA-approved — specifically for reducing excess abdominal fat (lipodystrophy) in HIV-infected patients — and has robust clinical trial data demonstrating significant visceral fat reduction. Sermorelin is an older GHRH(1-29) analog with decades of clinical history, formerly FDA-approved for pediatric GH deficiency (brand Geref, now discontinued), and widely used off-label in anti-aging clinics for general GH optimization.

Side-by-side comparison diagram of Sermorelin and Tesamorelin mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaSermorelinTesamorelin
Primary mechanismGHRH receptor agonist — bioidentical GHRH(1-29) fragmentGHRH receptor agonist — modified GHRH(1-44) with trans-3-hexenoic acid
FDA approval statusPreviously FDA-approved (Geref) for pediatric GH deficiency; brand discontinuedCurrently FDA-approved (Egrifta/Egrifta SV) for HIV-associated lipodystrophy
GH release potencyModerate GH stimulation — effective but less potent per dose than tesamorelinMore potent GH stimulation — stronger and more consistent GH/IGF-1 elevation in clinical trials
Visceral fat reductionSome evidence for body composition improvement, less specific dataStrong clinical evidence — 15–18% visceral fat reduction in Phase III trials
Typical dosage200–300 mcg subcutaneous, once daily before bed2 mg subcutaneous, once daily (FDA-approved dose)
Half-life~10–20 minutes~26–38 minutes
Amino acid sequence29 amino acids — the biologically active N-terminal fragment of native GHRH44 amino acids — full-length GHRH with a trans-3-hexenoic acid modification
Clinical trial dataModerate — older studies from 1980s–1990s, primarily in pediatric GH deficiencyExtensive — multiple large Phase III trials (>800 patients), published in NEJM and JAMA
Cognitive effectsLimited data on cognitive outcomesEmerging evidence for neuroprotective effects — improved cognition in studies of HIV patients and mild cognitive impairment
Side effectsMild — injection site reactions, facial flushing, headacheMild to moderate — injection site reactions (erythema, pruritus), arthralgia, peripheral edema
AvailabilityWidely available through compounding pharmacies and anti-aging clinicsPrescription-only (FDA-approved); some compounding pharmacies; significantly more expensive
Approximate monthly cost$50–$100 (compounding); $200–$400 (clinic protocol)$500–$1,000+ (compounding); $1,500–$3,000+ (brand Egrifta)

When to Choose Each

Choose Sermorelin

General anti-aging and GH optimization on a budget, patients who want a well-tolerated peptide with long clinical history, those stacking with ipamorelin or GHRP-2 for synergistic GH release

Choose Tesamorelin

Targeted visceral fat reduction, patients with HIV-associated lipodystrophy (FDA-approved indication), those seeking the most clinically validated GHRH therapy, individuals with cognitive decline concerns

Verdict

Tesamorelin is the objectively more potent and better-studied GHRH analog with FDA approval, proven visceral fat reduction, and emerging cognitive benefits — but it comes at a significantly higher cost. Sermorelin is the practical choice for most anti-aging and GH optimization protocols: it is well-tolerated, widely available from compounding pharmacies, affordable, and has decades of clinical use behind it. For patients specifically targeting visceral fat reduction or those who want the strongest evidence-backed GHRH therapy, tesamorelin is worth the premium. For general GH optimization, improved sleep, recovery, and body composition on a budget, sermorelin (often stacked with ipamorelin) remains the most popular option.

References

  1. Tesamorelin, a human growth hormone releasing factor analogue, reduces visceral fat in HIV-infected patients: a randomized, double-blind, placebo-controlled trial (NEJM) (2007) — PubMed
  2. Effects of tesamorelin on visceral fat and liver fat in HIV patients with abdominal fat accumulation (2014) — PubMed
  3. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (1999) — PubMed
  4. Tesamorelin effects on brain structure and function among HIV-infected patients: a double-blind placebo-controlled study (2017) — PubMed
  5. Growth hormone-releasing hormone and its analogs: clinical therapeutic utility and mechanism of action (2007) — PubMed

Frequently Asked Questions

Is tesamorelin worth the extra cost over sermorelin?
It depends on your goals. If visceral fat reduction is a primary objective, tesamorelin has significantly stronger clinical evidence — Phase III trials showed 15–18% reduction in trunk fat. For general anti-aging and GH optimization, sermorelin (especially stacked with ipamorelin) provides excellent results at a fraction of the cost. Tesamorelin also has emerging data on neuroprotection and cognitive benefits that sermorelin lacks.
Can tesamorelin be used for anti-aging like sermorelin?
Yes, though its FDA approval is specifically for HIV lipodystrophy, many anti-aging clinics prescribe tesamorelin off-label for GH optimization and body composition improvement. Its stronger potency and longer half-life make it arguably superior to sermorelin for these purposes, but the higher cost limits its practical use in this context.
Do sermorelin and tesamorelin suppress natural GH production?
No — this is a key advantage of GHRH analogs over exogenous HGH. Both sermorelin and tesamorelin stimulate the pituitary to release its own GH, preserving the natural feedback loop and pulsatile secretion pattern. There is no pituitary suppression or shutdown with either peptide, which is why they are considered safer for long-term use than direct GH replacement.
Can I stack sermorelin or tesamorelin with ipamorelin?
Absolutely. Combining a GHRH analog (sermorelin or tesamorelin) with a GHRP (ipamorelin) exploits the well-documented synergy between the two receptor pathways, producing GH release significantly greater than either peptide alone. Sermorelin + ipamorelin is the most popular and cost-effective stack. Tesamorelin + ipamorelin is less common due to cost but would theoretically provide even stronger results.
What kind of blood work should I get while using sermorelin or tesamorelin?
Regular monitoring is commonly recommended when using GHRH analogs. Key markers include IGF-1 levels (to confirm GH axis stimulation and ensure levels remain within a safe range), fasting blood glucose and insulin (to check for insulin resistance), HbA1c, and a basic metabolic panel. Some practitioners also recommend monitoring thyroid function, cortisol levels, and lipid panels. Baseline blood work before starting therapy is considered important for comparison. Testing every 3 to 6 months during active use is a common protocol. Consulting a healthcare provider experienced in peptide therapy is recommended to determine the appropriate monitoring schedule.

Explore next